NCT00452400CompletedPhase 2
Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (3 - 4 Doses) Delivered by the Respimat® Inhaler in Patients With COPD
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 409
- Locations
- 44
- Primary Endpoint
- Trough FEV1 Response After 4 Weeks
Study Overview
Brief Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount of the medication found in your blood).
Study Design
- Study Type
- Interventional
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions
- •All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:
- •Patients must have relatively stable, moderate to severe airway obstruction with a post-bronchodilator FEV1  30% of predicted normal and < 80% of predicted normal and a post-bronchodilator FEV1 / FVC < 70% at Visit 1
- •Male or female patients, 40 years of age or older
- •Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded
- •Patients must be able to perform technically acceptable pulmonary function tests and PEFR measurements, and must be able to maintain records (Patient Daily e-Diary) during the study period as required in the protocol
- •Patients must be able to inhale medication in a competent manner from the Respimat® inhaler and from a metered dose inhaler (MDI).
Exclusion Criteria
- •Selection of relevant exclusion criteria:
- •Patients with a history of asthma or a total blood eosinophil count 600/mm
- •Patients with any of the following conditions:
- •a diagnosis of thyrotoxicosis
- •a diagnosis of paroxysmal tachycardia (>100 beats per minute)
- •a marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval > 450 ms).
- •a history of additional risk factors for Torsade de Pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT Syndrome)
- •Patients with any of the following conditions:
- •a history of myocardial infarction within 1 year of screening visit (Visit 1)
- •a diagnosis of clinically relevant cardiac arrhythmia
- •known active tuberculosis
- •a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)
- •a history of life-threatening pulmonary obstruction
- •a history of cystic fibrosis
- •clinically evident bronchiectasis
- •a history of significant alcohol or drug abuse
- •Patients who have undergone thoracotomy with pulmonary resection
- •Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
- •Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program
- •Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)
- •Pregnant or nursing women
- •Women of childbearing potential not using a highly effective method of birth control
- •Patients who have previously been randomized in this study or are currently participating in another study
- •Patients who are unable to comply with medication restrictions.
Outcomes
Primary Outcomes
Trough FEV1 Response After 4 Weeks
Time Frame: Baseline and 4 weeks
Trough FEV1 is defined as the mean of the two FEV1 values (performed at -1 hour and -10 minutes prior to test-drug inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response is defined as the change from baseline in trough FEV1. Baseline FEV1 is the mean of the two pre-treatment FEV1 values measured at Visit 2 (- 1 hour and - 10 minutes) prior to administration of the first dose of study medication.
Secondary Outcomes
- Trough FVC Response After 2 Weeks(Baseline and 2 weeks)
- Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks(4 weeks)
- Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1(1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at day 1)
- Weekly Mean Evening PEFR After 4 Weeks(4 weeks)
- Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)(Baseline and 4 weeks)
- Trough FEV1 Response After 2 Weeks(Baseline and 2 weeks)
- Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4(1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4)
- Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4(1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4)
- Peak FVC (0-3h) Response After 4 Weeks(1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks)
- Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2(1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2)
- Peak FEV1 (0-3h) Response After 1 Weeks(1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week)
- Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 1 Week(Baseline and 1 week)
- Trough FEV1 Response After 1 Week(Baseline and 1 week)
- Trough FVC Response After 1 Week(Baseline and 1 week)
- Trough FVC Response After 4 Weeks(Baseline and 4 weeks)
- Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1(1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1)
- Peak FEV1 (0-3h) Response At Day 1(1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1)
- Peak FEV1 (0-3h) Response After 2 Weeks(1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks)
- Peak FEV1 (0-3h) Response After 4 Weeks(1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks)
- Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 2 Weeks(Baseline and 2 weeks)
- Area Under Curve From 0 to 3 Hours (AUC0-3)(Baseline and 4 weeks)
- Maximum Concentration (Cmax)(Baseline and 4 weeks)
- Time From Dosing to the Maximum Concentration (Tmax)(Baseline and 4 weeks)
- Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)(Baseline and 4 weeks)
- Maximum Concentration at Steady State (Cmax,ss)(Baseline and 4 weeks)
- Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination(4 weeks)
- Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response at Day 1(baseline and day1)
- Forced Expiratory Volume in 1 Second (FEV1) (Unsupervised) Area Under Curve 6-12 h (AUC 6-12h) Response After 4 Weeks(Baseline and 4 weeks)
- Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEFR) After 4 Weeks(4 weeks)
- Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)(Baseline and 4 weeks)
- Laboratory Testing: Average Change From Baseline of Potassium(Baseline and day 29)
- Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)(Baseline and 4 weeks)
Investigators
Study Sites (44)
Loading locations...
Similar Trials
Completed
Phase 2
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With AsthmaAsthmaNCT00467740Boehringer Ingelheim296
Completed
Phase 2
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPDPulmonary Disease, Chronic ObstructiveNCT00824382Boehringer Ingelheim328
Completed
Phase 2
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)Pulmonary Disease, Chronic ObstructiveNCT00696020Boehringer Ingelheim360
Completed
Phase 2
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT00720499Boehringer Ingelheim141
Completed
Phase 3
12 / 48 Week Pivotal PFT vs PBO in COPD IPulmonary Disease, Chronic ObstructiveNCT00782210Boehringer Ingelheim625